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including surgery vs. 11.7 months for the 66 pts not resected.
Among the 164 pts who completed all therapy, no difference
in median survival was observed between low CA199 and
elevated CA19-9 pts; 36.7 months vs. 33.1 months, p = 0.89.
Conclusions: An elevated CA19-9 at diagnosis did not
predict a failure to complete neoadjuvant therapy and was not
associated with inferior survival. These data suggest two
cautionary notes: an elevated CA19-9 at diagnosis should not
be considered synonymous with advanced (non-surgical)
disease; and, a low/normal CA19-9 should not be interpreted
as a predictor of favorable outcome (and used to justify a
surgery first strategy).
LO-A.06 ONE YEAR EXPERIENCE
OF CHARACTERIZATION OF
GENETIC RISK IN A HIGH-RISK
PANCREATIC CLINIC
K. Flores, K. Dinh, E. Rouleau, W. Wassef, J. LaFemina
University Of Massachusetts, Worcester, MA
Background: Despite the established benefit of early detec-
tion in pancreatic cancer (PDAC) prognosis, high-risk pan-
creatic clinics are less common than their breast or colon
counterparts. One of the difficulties of establishing a high-
risk clinic is delineating which individuals are “high-risk.”
Methods: We retrospectively examined patients referred for
genetic counseling for PDAC from January 2009-June 2014.
Patients were referred for a personal and/or family history of
PDAC or a potential diagnosis of hereditary pancreatitis
(HP).
Results: 75 patients were referred for genetic counseling; 36
underwent testing. Twelve (33%) mutation carriers were
identified, demonstrating a positivity rate higher than in high-
risk clinics for other malignancies. The most common reason
to decline testing was lack of insurance. 11% of patients with
a family history of PDAC were found to carry a mutation.
20% of those a personal history of PDAC were found to carry
a mutation. Ten of 43 patients with a personal history of
chronic pancreatitis were found to carry ≥1 mutations. Of
these, 8 were heterozygous for CFTR mutations, 1 was
CFTR homozygous, and 1 was homozygous for SPINK1
mutations.
Conclusion: This study illustrates criteria for the highest
yield of genetic evaluation for high-risk of PDAC. Insurance
coverage for unaffected relatives is lacking. Identification of
a causative mutation in an affected family member allows for
cost-effective targeted testing in at-risk relatives. Individuals
with apparently idiopathic pancreatitis, onset of pancreati-
tis < 30 years, and those with a family history of pancreatitis
or PDAC are candidates for genetic evaluation.
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LO-B.04 SURGICAL RESECTION VERSUS
ABLATION FOR HEPATOCELLULAR
CARCINOMA LESS THAN 3CM: A
POPULATION BASED ANALYSIS
J. T. Miura, R. T. Groeschl, F. M. Johnston, S. Tsai,
K. K. Christians, K. K. Turaga, T. C. Gamblin
Medical College Of Wisconsin, Department Of Surgery,
Milwaukee, WI
Background: Ablation for ≤3 cm hepatocellular carcinoma
(HCC) has been demonstrated to be an effective treatment
strategy. Whether ablation achieves a similar survival benefit
as compared to surgical resection for early stage HCC
remains ill defined. The present study sought to examine the
outcomes of patients with ≤3 cm HCC following ablation
versus resection.
Methods: Patients treated by ablation or surgical resection
for ≤3 cm T1 HCC were identified from the National Cancer
Database (2002–2011). Cox proportional hazards models
were used to assess overall survival (OS) between treatment
types (ablation vs resection) following adjustment for age,
gender, alpha-fetoprotein (AFP), Charlson Comorbidity
Score, and cirrhosis.
Results: A total of 2,855 patients underwent ablation
(n = 1,984) or resection (n = 871) for solitary HCC ≤3 cm.
The median age of the collective cohort was 61 (IQR: 55–70)
with the majority being male (n = 2,007, 70.1%). Patients
treated with ablation as compared to resection had a higher
frequency in AFP elevation (46.5% vs 39%, p < 0.01) and
presence of cirrhosis (22.2% vs 14.9%, p < 0.01). Unad-
justed OS at 3 and 5 years was greater following resection
(67%, 55%) versus ablation (52%, 36%, p < 0.01). In
multivariable models, resection was independently associ-
ated with improved OS (HR: 0.65, 95% CI: 0.51–0.83;
p < 0.01).
Conclusion: While more invasive, resection of HCC ≤3 cm
results in better long-term survival as compared to ablation.
Treatment strategies for small solitary HCC should empha-
size a resection first approach, with ablation being reserved
for patients precluded from surgery.
[Correction added on 24 February 2015. Moved “LO-B.04
“SURGICAL RESECTION VERSUS ABLATION FOR
HEPATOCELLULAR CARCINOMA LESS THAN 3CM: A
POPULATION BASED ANALYSIS” before “LO-B.01”.]
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LO-B.01 POST-EMBOLIZATION
SYNDROME AS AN EARLY PREDICTOR
OF LONG-TERM OUTCOME
AFTER TRANSARTERIAL
CHEMOEMBOLIZATION FOR
HEPATOCELLULAR CARCINOMA
M. C. Mason1,2, N. N. Massarweh2,3, A. Salami2,
M. A. Sultenfuss4, D. A. Anaya2,3
1Michael E DeBakey Department Of Surgery, Baylor
College Of Medicine, Houston, TX; 2VA HSR&D Center
For Innovations In Quality, Effectiveness And Safety,
Houston, TX; 3Michael E DeBakey Department Of Surgery
– Division Of Surgical Oncology, Houston, TX;
4Department Of Radiology, Baylor College Of Medicine,
Houston, TX
Introduction: Transarterial chemoembolization (TACE) is
commonly used in the management of hepatocellular carci-
noma (HCC) patients not candidates for curative resection or
as a bridge to transplantation. A common post-TACE com-
plication is post-embolization syndrome (PES). The goal of
this work was to evaluate PES as an early, post-procedural
predictor of treatment outcome.
Methods: A retrospective cohort study of HCC patients who
underwent TACE at a tertiary referral center was performed
(2009–2014). Patients were excluded if they had other thera-
pies in combination with TACE. Patients were categorized
based on whether they presented with PES, defined as fever
with or without abdominal pain within 2 weeks of TACE.
The primary outcome was overall survival (OS) evaluated
using multivariate Cox regression while adjusting for rel-
evant demographic and clinical characteristics.
Results: Among 144 patients treated with TACE alone
(70.1% ≥65 years and 44.4% Child’s B or C cirrhosis),
36.1% experienced PES. Median follow-up for the cohort
was 11.4 (0.6–49.9) months. Median and 3-year OS were 16
months and 18.0% in the PES group versus 25 months and
41.0% in the no PES group (log-rank, p = 0.027). After mul-
tivariate modeling, patients with PES had a higher risk of
death compared to non-PES patients (Hazard Ratio 1.94;
95% Confidence Interval 1.12–3.34, P = 0.016).
Conclusion: Patients who suffer from PES have signifi-
cantly worse overall survival even after adjusting for impor-
tant factors. Future investigation into the pathophysiologic
mechanism underlying PES may help identify patients at
increased risk of death and better select treatment strategies
for HCC patients with different biologic behavior.
LO-B.02 DISPARITIES IN CARE FOR
PATIENTS WITH CURABLE
HEPATOCELLULAR CARCINOMA
R. S. Hoehn, D. J. Hanseman, K. Wima, A. Ertel,
P. L. Jernigan, D. E. Abbott, S. A. Shah
Department Of Surgery, University Of Cincinnati School
Of Medicine, Cincinnati, OH USA
Objectives: The incidence of hepatocellular carcinoma
(HCC) is increasing in the United States. The aim of this
study was to evaluate the use and outcomes of surgical man-
agement of early stage HCC.
Methods: The National Cancer Database (NCDB) was
queried for all patients diagnosed with curable HCC (Stage
I/II) from 1998-2011 (n=43,859). Demographic information,
tumor characteristics, treatment trends, and outcomes were
assessed. Multivariate logistic regression was used to deter-
mine predictors of having surgery and of long-term survival.
Median follow-up was 2.5 years.
Results: Patients who underwent surgery (n=17,406;
39.7%) received surgical resection (34.6%), liver transplant
(28.7%), radiofrequency ablation (27.1%), or other therapies.
While surgery was associated with improved survival (HR
0.76, 95% CI 0.72-0.79), it was only performed on 42% of
stage I patients and 50% of patients with tumors smaller than
2cm. Asian and white patients were more likely than black
patients to undergo surgery, as were patients from zip codes
in the highest education and income quartiles compared to
the lowest (p<0.001). Predictors for not having surgery
included black race, government insurance, and treatment at
a non-academic center (Table 1). Postoperative mortality and
long-term survival were better for patients with private insur-
ance or those treated at an academic center (Table 1).
Conclusion: In this analysis of the NCDB, fewer than half
of patients with curable HCC underwent surgery, and this
appears to be associated with race, socioeconomic status and
access to care. Further research is necessary to understand
barriers and disparities in care for curable HCC patients.
LO-B.03 THE MODIFIED RESPONSE
EVALUATION CRITERIA IN SOLID
TUMORS (MRECIST) PREDICTS
SURVIVAL FOLLOWING
TRANSARTERIAL
CHEMOEMBOLIZATION (TACE) FOR
HEPATOCELLULAR CARCINOMA
N. S. Haywood, N. S. Haywood, S. Saddekni,
K. H. Gennaro, D. T. Redden, J. A. White, S. H. Gray,
A. K. Aal, D. E. Eckhoff, D. A. DuBay
University Of Alabama At Birmingham, Birmingham, AL
Background: Transarterial chemoembolization (TACE) is
the most common oncologic treatment administered for the
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treatment of hepatocellular carcinoma (HCC) in the US. The
impact of TACE-induced HCC tumor necrosis on patient
survival is poorly defined.
Hypothesis: We hypothesize that survival will be superior
in HCC patients with increased TACE-induced tumor
necrosis.
Methods: All first TACE interventions for HCC performed
at a single institution from 2008–2013 were retrospectively
reviewed (n = 344, Table 1). HCC tumor response to TACE
was quantified via the modified response evaluation criteria
in solid tumors (mRECIST) criteria. Differences in survival
were compared using the log-rank test. A multivariable
analysis of survival predictors was completed with a Cox
proportional hazard model.
Results: The median survival following TACE treatment
for HCC varied according to the mRECIST response
(p = 0.012), with the longest survival observed in patients
with a complete response and shortest survival in patients
with progressive disease (Table 1) Patients with a complete
response had the lowest frequency of repeat TACE, and
highest probability of receiving a liver transplant (Table 1).
The mRECIST score remained significantly associated with
survival (p = 0.0005) in a multivariable model of survival
predictors controlling for age, gender, race, tumor size and
number, and Child’s score.
Conclusions: The mRECIST response to TACE in patients
with HCC was predictive of survival, the need for repeat
TACE, and the probability of receiving a liver transplant.
However, the absolute differences in median survival
between mRECIST categories were not as large as predicted.
LO-B.05 ROLE OF SURGICAL
RESECTION AND LOCOREGIONAL
THERAPY IN PATIENTS WITH STAGE 3
HEPATOCELLULAR CARCINOMA A
RETROSPECTIVE REVIEW FROM THE
NATIONAL CANCER DATABASE
R. Seshadri, E. H. Baker, S. W. Ross, M. Templin,
R. Z. Swan, J. B. Martinie, D. A. Iannitti
Carolinas Medical Center, Charlotte, NC
Introduction: In advanced stages, hepatocellular carcinoma
(HCC) is often associated with major vascular involvement
(cava, portal vein). Our aim was to analyze the role of sur-
gical resection (SR) and locoregional therapy (LRT) in these
advanced stage patients to determine if there was a survival
benefit.
Methods: The study is a retrospective analysis from the
Commission on Cancer’s National Cancer Data Base
(NCDB) between 1998–2011. 148,882 patients with liver
cancer were identified, of which 126,858 had HCC. Of these,
64,227 patients (1998–2006) had 5-year survival data avail-
able and 16,036 patients had Stage 3A disease based on
AJCC classification. Of these patients, 1,346 had SR, 1,003
had LRT and 11,942 patients had neither intervention.
Kaplan-Meier curves and log rank tests were used for statis-
tical analysis.
Results: 14,291 patients met analysis criteria. Mean age
(years) in the SR, LRT and no intervention group were 62.5
64.3 and 64.2 respectively. Most patients were males in all 3
groups (77.5%, 74.5% and 68.1%). Mean tumor size (cm) in
the 3 groups was 9.8, 6.4 and 8.4 respectively. SR and LRT
were primarily performed in major academic and compre-
hensive cancer programs compared to community cancer
programs and other centers (SR: 93% vs 7%; LRT: 94.6% vs
5.4%). The median 5 year survival (months) was 26.55 in SR;
16.36 in LRT and 4.8 in no intervention group. (p < 0.0001).
Conclusion: Surgical resection and locoregional therapy
offer a survival benefit in select patients diagnosed with
Stage 3 HCC.
LO-B.06 CLINICAL OUTCOMES OF
RESECTION VS. ABLATION OF SINGLE
NODULE HEPATOCELLULAR
CARCINOMA IN THE ERA OF ORGAN
SHORTAGE. SHOULD WE EXTEND
THE LIMITS?
O. C. Kutlu1, M. Wachtel2, S. Dissanaike1
1TTU HSC Dept Of Surgery, Lubbock, TX; 2TTU HSC Dept
Of Pathology, Lubbock, TX
Introduction: Donor shortage is a limitation for transplan-
tation, leaving resection as the modality of choice for HCC.
Radiofrequency ablation(RFA) is an option for early HCC
patients or for bad surgical candidates. Studies are being
published investigating the use of RFA in larger tumors with
smaller ablative margins. We aimed to compare RFA to other
modalities in a large epidemiological database.
Methods: SEER database was queried for patients at least
20 years age, diagnosed between 2004–8, no metastatic
disease, with tumors less than 3.5 cm. Table 1 displays data
of importance. Binomial logit regression calculated estimates
and standard errors of odds ratios of death at 1 y and 3 y,
using R3.1.1. Null hypotheses were rejected if P < 0.05/
2 = 0.025.
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Results: Figure 1 displays the results of binary logit regres-
sion. While survival was similar in RFA and Resection at 1 y,
at 3 y RFA fared worse. Elevated AFP and age were not
significant at 1 y, but were associated with increased odds of
death at 3 y. No assumptions of general linear models were
found to be violated. No influential outlier groups were seen.
Conclusion: Researchers are seeking ways to facilitate
resection and RFA in HCC. Studies have been published
discussing RFA and margins <1 cm for HCC up to 5 cm’s in
size. RFA probes have been shown to produce a cavity size of
4.5 cm’s in diameter. Although 3.5 cm was the largest tumor
size in our study, three year outcomes of RFA were signifi-
cantly inferior to resection and transplantation, reaching
almost twice the odds of death.
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LO-C.01 SPLIT-LIVER
TRANSPLANTATION: REPORT OF
RIGHT AND LEFT GRAFTS OUTCOMES
FROM A MULTICENTER ARGENTINEAN
GROUP
E. Halac1, M. Dip1, F. Alvarez2, J. Leiva Espinoza2,
E. Quinonez3,4, P. Romero 7, F. Nievas5, R. Maurette6,
C. Luque8, D. Matus1, P. Surraco1, M. Fauda5,6,
G. Gondolesi7, L. McCormack3, J. Mattera2,4,
O. Imventarza1
1Hospital Nacional De PediatrJuan P Garrahan, CABA,
CABA; 2Hospital Italiano De Buenos Aires, CABA, CABA;
3Hospital Aleman, CABA, CABA; 4Hospital El Cruce Dr.
Nestor Carlos Kirchner, Florencio Varela, BUENOS
AIRES; 5Hospital Universitario Austral, Derqui, BUENOS
AIRES; 6Hospital Britanico, CABA, CABA; 7Fundacion
Favaloro, CABA, CABA; 8Hospital General De Ninos Dr
Ricardo Gutierrez, CABA, CABA
Grafts from split livers constitute an accepted approach to
expand the donor pool. There was a significant interest from
most of the Argentinean centers to increase in the use of this
technique over the last 5 years.
Aims: Describe and analyze the outcomes of right (RSG)
and left (LSG) grafts from a multicenter study.
Methods: Multicenter retrospective study including data
from 111 recipients of split liver grafts between 1/1/2009–
31/12/2013. Incidence of surgical complications, patient and
graft survival, and factors that affected RSG and LSG sur-
vival were analyzed.
Results: Grafts types were 57 LSG and 54 RSG. Median
follow up times for LSG and RSG were 46 and 42 months
respectively. The 36-month patient and graft survivals for
LSG were 83% and 79%, and for RSG was 78% and 69%
respectively. Retrasplantation rates for LSG and RSG were
3.5% and 11% respectively. Artherial complications were the
most common cause of early retransplantation (less than 12
months). Cold ischemia time (CIT) longer than 10 hours and
the use of high risk donors (older than 40 years or BMI ≥30
or ≥5 days ICU) were independent factors for diminished
graft survival in RSG. No analyzed variables were associated
with worse graft survival in LSG. Biliary complications were
the most frequent in both groups(57% in LSG and 33% in
RSG).
Conclusions: Partial grafts obtained from liver splitting are
an excellent option for patients in need of liver transplanta-
tion, and have the potential to alleviate the organ shortage.
Adequate donor selection and reducing CIT are crucial for
optimizing results.
LO-C.02 INTRAOPERATIVE
HYPOTENSION DURING LIVER
TRANSPLANTATION IS ASSOCIATED
WITH DECREASED ONE YEAR PATIENT
AND GRAFT SURVIVAL
P. F. Sauer, D. A. DuBay, P. A. MacLennan,
J. H. Crawford, J. A. White, S. H. Gray, D. E. Eckhoff
University Of Alabama At Birmingham, Birmingham, AL
Introduction: Patients with end-stage liver disease experi-
ence peripheral vasodilatation and have lower mean arterial
blood pressure (MAP) at baseline. However, it is unclear how
intraoperative hypotension effects post-liver transplant
patient and graft survival. We hypothesized that increased
duration of MAP <60 mmHg (MAP <60) was associated
with decreased patient survival.
Methods: A retrospective study of adult liver transplant
patients from a single center was performed. Anesthesia
records were used to quantify the intraoperative duration of
MAP <60. Patients were stratified into 3 groups based on
cumulative duration MAP <60: <30 minutes, 30–59 minutes
and 60+ minutes. Blood product usage, length of hospitali-
zation, vasoactive drug administration, and 1-year patient
and graft survival were measured. MAP <60 duration groups
were compared using ANOVA, Chi-square tests, and Log-
Rank tests for continuous and categorical variables, and sur-
vival curves, respectively.
Results: Overall 565 patients were included: <30 minutes
(N = 461, 81.6%), 30–59 minutes (N = 42, 7.4%), and 60+
minutes (N = 62, 11.0%). Patients in the 60+ minutes group
had the highest MELD score (27.7, p = 0.0051), received
the most units of pRBCs (5.5, p < 0.0001), FFP (2.96,
p < 0.0001), platelets (1.5, p < 0.0001) and intravenous phe-
nylephrine (14487 μg, p < 0.0001), and had the lowest 1-year
patient (72.2%, p = 0.0060) and graft survival (72.2%,
p = 0.0063)(Table).
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